Latest studies
- RecruitingPHASE3
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study is testing a new medicine, plozasiran, for people with very high triglycerides who have had pancreatitis. It will check if the medicine is safe and helps reduce the risk of future pancreatitis attacks. Participants will get either the study medicine or a dummy medicine.
Severe HypertriglyceridemiaLatvia - AuthorisedTherapeutic exploratory (Phase II)
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
This study is testing a new tablet called CRD-4730 for adults with heart failure. Researchers want to see if the medicine can help the heart pump blood better, ease everyday symptoms, and improve quality of life. Participants will take either the study drug or a dummy pill for 24 weeks.
heart failureLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
This study tests a new medicine called claseprubart (DNTH103) for generalised myasthenia gravis, a condition that causes muscle weakness. Researchers want to see if the medicine safely improves muscle strength and helps with daily activities compared to a dummy drug (placebo) in adults aged 18 and older.
generalized Myasthenia gravisLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, 52-Week, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab in Adult Subjects With Prurigo Nodularis Who are Inadequately Controlled on Topical Therapies or Not Eligible for Topical Therapies
This study tests whether a new medicine called rocatinlimab helps adults with prurigo nodularis. This skin condition causes intensely itchy, firm lumps to form on the skin. The trial checks if the treatment can reduce severe itching and heal skin bumps when prescription creams have not provided enough relief.
Prurigo NodularisLatvia - RecruitingTherapeutic confirmatory (Phase III)
Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia (SHASTA-4 Study)
This Phase 3 clinical study tests a new injection called plozasiran for adults with very high blood fats, known as triglycerides. Researchers want to see if plozasiran can safely lower these fat levels over 12 months compared to a dummy jab, reducing the risk of painful pancreas inflammation.
Severe hypertriglyceridemia (SHTG)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA)
This phase 3 study tests a new treatment called UGN-103 for non-muscle invasive bladder cancer. UGN-103 is a medicine placed directly into the bladder to help clear early-stage cancer cells. Researchers want to see how well it works, how safe it is, and if it can reduce the need for surgery.
Nonmuscle Invasive Bladder CancerLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
This clinical study tests two new medicines, REGN7508 and REGN9933, for adults with atrial fibrillation (an irregular heartbeat). It aims to find out if these treatments can safely stop blood clots and strokes in people who cannot take standard blood-thinning tablets due to a high risk of bleeding.
Atrial Fibrillation (AF)Latvia - AuthorisedPhase II and Phase III (Integrated)
A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study
This study tests a new eye injection called OCUL101 for wet age-related macular degeneration (wet AMD). Researchers want to see how safe it is and if it works as well as or better than Eylea, a standard NHS eye treatment, at protecting or improving sight.
Neovascular age-related macular degeneration (nAMD)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis
This study looks at a new drug called nemolizumab for adults with moderate-to-severe eczema (atopic dermatitis). Researchers want to see how safe the medicine is when used over a long period. They also want to find out how well it clears skin, calms itchiness, and improves sleep.
Atopic DermatitisLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Double-Blind, Placebo-controlled, Safety and Efficacy Study of VI-0106 (Extended-release Tacrolimus) in Subjects with PAH and Functional Limitations Despite Optimized Therapy with Available PAH Medications
This study tests whether a medicine called VI-0106 can help people with pulmonary arterial hypertension (PAH). PAH is high blood pressure in the lungs. Researchers want to see if adding this tablet to existing treatments helps people walk further and lowers the chance of their condition getting worse.
Pulmonary Arterial Hypertension (PAH)Latvia - AuthorisedPhase III and phase IV (Integrated)
A Phase 3b/4, Multicenter, Parallel-Group, Double-Blind, Placebo-Controlled, Two-Arm, Long-Term Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium on Clinical Outcomes in Participants with Primary Biliary Cholangitis (PBC)
This study is looking at a medicine called saroglitazar magnesium for people living with primary biliary cholangitis (PBC). Researchers want to see if this daily tablet can protect the liver from long-term damage, reduce extreme tiredness, and lower the risk of serious complications or needing a liver transplant.
Primary Biliary Cholangitis (PBC)Latvia - AuthorisedTherapeutic confirmatory (Phase III)
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
This clinical trial is testing new blood-thinning medicines for adults with peripheral artery disease who recently had a procedure to restore blood flow in their legs. Researchers want to find out if these medicines can prevent serious blood clots, heart attacks, and amputations without causing major bleeding problems.
Peripheral Artery DiseaseLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)
This study tests a new medicine called REGN7508 for adults with atrial fibrillation, an irregular heartbeat. Researchers want to see if it prevents strokes as effectively as the standard blood thinner, apixaban, while causing less bleeding. Participants receive either the new treatment or the standard medicine alongside regular check-ups.
Atrial Fibrillation (AF)Latvia - RecruitingTherapeutic confirmatory (Phase III)
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
The ZEUS study is looking at whether a new medicine called ziltivekimab can protect people with heart and kidney problems. Researchers want to see if lowering body swelling and inflammation can reduce the chances of serious health events like heart attacks, strokes, or worsening kidney disease.
Atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammationLatvia - AuthorisedTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)
This clinical trial looks at a new injection form of letrozole, a common hormone therapy for advanced breast cancer. Researchers want to see if this long-acting injection works just as well as daily tablets at slowing cancer growth, while also comparing side effects like joint and muscle aches.
HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancerLatvia - RecruitingTherapeutic exploratory (Phase II)
An Adaptive Phase 2a/2b, Randomized, Double-Blind, Parallel-Group Study to Investigate the Safety and Efficacy of LY3541860 Compared to Placebo in Slowing the Occurrence of New T1 Gadolinium-Enhancing Lesions in Adult Participants with Relapsing Multiple Sclerosis
This study is looking into a new medicine, LY3541860, for people with relapsing multiple sclerosis (RMS). Researchers want to see if it can reduce the number of new spots on the brain (lesions) compared to a dummy treatment (placebo).
Relapsing Multiple SclerosisLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicenter Study to Compare Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BP05 Versus EU-Approved Lucentis® in Patients with Wet (Neovascular) Age-Related Macular Degeneration
This study is testing a new version of an eye medicine, ranibizumab (like Lucentis), for wet age-related macular degeneration. Researchers want to see if the new version works as well and is as safe as the original to help people see better.
wet macula degenerationLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Multi-national Phase IIIb, Double-blind, Placebo-controlled Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years old with Birch Pollen-induced Allergic Rhinoconjunctivitis with or without Asthma
This study is testing a new treatment called STALORAL® Birch for children and teenagers aged 5 to 17 who suffer from hay fever (allergic rhinoconjunctivitis) caused by birch pollen. It looks at how safe and effective the treatment is, and if it could help with asthma too.
Birch Pollen-induced Allergic RhinoconjunctivitisLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
This study is looking at a medicine called ozanimod for people with Crohn's disease that is moderate to severe. It wants to see how well the medicine helps reduce their symptoms and improve their gut health over a long period. Researchers will also check how it affects COVID-19 antibody levels.
Moderately to Severely Active Crohn's DiseaseLatvia - RecruitingTherapeutic confirmatory (Phase III)
A prospective, randomized, double-blind, placebo-controlled, two-stage, multicenter study with an open-label extension period to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity in children and adolescents with cerebral palsy
This study is testing a medicine called NT 201 (also known as Xeomin) for children and teenagers with cerebral palsy who have stiff leg muscles. It aims to see if the medicine helps reduce the stiffness and improve movement, compared to a dummy treatment.
Pediatric lower limb (LL) spasticity (SP) caused by cerebral palsy (CP)Latvia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction
This study is testing a new medicine, Tovinontrine, for people with a type of heart failure where the heart struggles to pump blood effectively. It aims to see if different doses are safe and if the medicine helps improve heart health over 12 weeks.
Heart failure (HF) with reduced ejection fraction (HFrEF)Latvia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new medicine called Danicopan for a type of age-related macular degeneration (AMD) called geographic atrophy (GA). Researchers want to see if the medicine can slow down vision loss and the growth of blind spots.
Geographic atrophy (GA) secondary to Age-related Macular Degeneration (AMD)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A trial comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® in children with growth hormone deficiency
This study is looking at a new way to give growth hormone treatment to children. Instead of daily injections, it's testing a weekly injection called Sogroya against the usual daily treatment, Norditropin. The main goal is to see if weekly Sogroya helps children grow as well as daily treatment.
Growth Hormone Deficiency in childrenLatvia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Thromboembolic diseaseLatvia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2, Dose-finding, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa Induction Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called Efavaleukin Alfa for people with moderate to severe Ulcerative Colitis. We want to see if it's safe and helps people feel better and get their condition under control within 12 weeks.
Ulcerative Colitis (UC)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
This study is looking at a new treatment for stomach cancer and cancer where the food pipe joins the stomach. It's comparing a drug called pembrolizumab combined with chemotherapy against chemotherapy alone, to see if it helps patients live longer and stops the cancer from coming back.
Gastric and gastroesophageal junction (GEJ) adenocarcinomaLatvia - RecruitingTherapeutic exploratory (Phase II)
A Phase 2 Long-Term Extension (LTE) Study to Evaluate The Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis
This study looks at a new medicine called Efavaleukin Alfa for people with moderate to severe ulcerative colitis. It's a long-term study to see how safe and effective the medicine is over a year or two, especially regarding side effects.
Ulcerative Colitis (UC)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.
This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.
Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)Latvia - RecruitingHuman Pharmacology (Phase I)- Other
Defining the Glucagon Unit: Investigating the Impact on Energy Expenditure and Glucose Level Deviation in healthy volunteers
This study for healthy men aged 18 and over investigates how different substances, including medicines for weight loss and hormones, affect the body's energy use and blood sugar levels. Researchers want to understand these effects to help treat conditions like obesity.
ObesityLatvia - RecruitingTherapeutic confirmatory (Phase III)
A phase 3, randomised, double-blind, placebo-controlled study assessing the efficacy and safety of gliclazide MR in patients with type 2 diabetes inadequately controlled with dapagliflozin with or without metformin.
This study looks at a medicine called gliclazide MR to see if it helps people with type 2 diabetes whose blood sugar isn't well controlled, even when using other common diabetes medicines like dapagliflozin or metformin. It aims to see if it's safe and effective.
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metforminLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED)
This study is testing a new medicine, Batoclimab, for people with an eye condition called Thyroid Eye Disease (TED). We want to see if this medicine can help reduce bulging eyes and improve other eye symptoms compared to a dummy medicine.
Thyroid Eye DiseaseLatvia - RecruitingTherapeutic confirmatory (Phase III)
A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes (PRO) in patients with relapsing multiple sclerosis (RMS) transitioning from fumarate-based RMS approved therapies or fingolimod.
This study looks at how well a medicine called Kesimpta works for people with a type of multiple sclerosis called relapsing multiple sclerosis (RMS). It also checks for side effects and how people feel on the treatment, especially those switching from other MS medicines.
relapsing multiple sclerosis (RMS)Latvia - RecruitingTherapeutic use (Phase IV)
Efficacy, safety, tolerability and quality of life of ongoing individually optimized lipid-lowering therapy with or without inclisiran (KJX839) – a randomized, placebo-controlled, double-blind multicenter phase IV study in participants with hypercholesterolemia
This study is looking at a new way to lower 'bad' cholesterol (hypercholesterolemia). It compares a new medicine called Inclisiran with usual treatments, to see if it's safe and helps people feel better and reach their cholesterol goals.
HypercholesterolemiaLatvia - RecruitingTherapeutic confirmatory (Phase III)
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS) KEYNOTE-091
This study looks at a drug called Keytruda after surgery for a type of lung cancer. It aims to see if Keytruda can stop the cancer from coming back for longer than a dummy treatment in patients with non-small cell lung cancer, especially those with certain cancer markers.
Stage IB (T ≥ 4 cm), II and IIIA NSCLCLatvia - RecruitingTherapeutic confirmatory (Phase III)
An Open-label Extension Study for Participants who Completed Study IMVT-1401-3201 or Study IMVT-1401-3202 to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)
This study looks at a new medicine called batoclimab for Thyroid Eye Disease (TED). It’s for people who have already taken part in similar batoclimab studies. We want to see how long their eyes stay improved after stopping the medicine and if it helps those who didn't respond before.
Thyroid Eye Disease (TED)Latvia - RecruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
This study looks at a new drug, abelacimab, compared to a standard drug, apixaban, for treating blood clots in veins (VTE) in people with cancer. The main goal is to see which drug is better at preventing new clots and causing less bleeding over six months.
venous thromboembolism (VTE)Latvia - RecruitingTherapeutic exploratory (Phase II)
Double-blind, randomised, placebo-controlled, dose-finding phase IIb trial to evaluate the efficacy, safety, and tolerability of a 12-week-treatment with Naronapride in adult participants with at least moderate idiopathic or diabetic gastroparesis
This study is testing a new medicine, Naronapride, for adults with stomach-emptying problems like gastroparesis. We want to see if it helps reduce symptoms like nausea and bloating, and if it's safe over 12 weeks.
Idiopathic or Diabetic GastroparesisLatvia - RecruitingPhase II and Phase III (Integrated)
A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
This study looks at a new medicine called abelacimab for people with cancer-related blood clots. It compares abelacimab to a common blood thinner, dalteparin, to see which is better at preventing new clots and causing fewer bleeds.
venous thromboembolism (VTE) in patients with gastrointestinal/genitourinary cancerLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, in Adults (OP0595-5)
This study is testing new medicines for serious urine infections. It compares them to a standard medicine to see if they are safe and work well for adults with complicated urine infections or kidney infections, checking if they clear the infection and make patients feel better.
Complicated urinary tract infection (cUTI) and acute uncomplicated pyelonephritis (AP)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Parallel Group, Multicentre Study to Compare Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, immunogenicity, of BP11 versus EU-Approved Xolair in patients With Chronic Spontaneous Urticaria Who Are Resistant to H1 Antagonist.
This study compares a new medicine (BP11) with an approved one (Xolair) for chronic hives that haven't responded to usual treatments. Researchers want to see if BP11 is safe and effective in reducing itching and other symptoms.
Chronic UrticariaLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study is testing a new treatment called OPT-302, given alongside an existing treatment (Eylea), for a serious eye condition called 'wet' Age-related Macular Degeneration (AMD). Doctors want to see if combining these treatments helps people see better than Eylea alone.
Neovascular Age-related Macular Degeneration (wet AMD)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Parallel-Group Treatment, Double-Blind, 2-Arm Study to Investigate the Comparative Efficacy, Safety, and Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects Aged 18 to 80 Years Inclusive with Moderate to Severe Active Ulcerative Colitis
This study is comparing two medicines, AVT16 and Entyvio, for people aged 18-80 with moderate to severe ulcerative colitis. It will check how well they work, how safe they are, and how the body reacts to them over 52 weeks. The main goal is to see if symptoms improve after 6 weeks.
Moderate to Severe Active Ulcerative ColitisLatvia - RecruitingTherapeutic confirmatory (Phase III)
A 52-week, randomized, double-blind, double-dummy, placebo- and active- controlled (Roflumilast, Daliresp® 500μg), parallel group, study to evaluate the efficacy and safety of two doses of CHF6001 DPI add-on to maintenance triple therapy in subjects with Chronic Obstructive Pulmonary Disease (COPD) and chronic bronchitis
This study looks at new inhaled medications for people with a type of lung disease called COPD. It aims to see if these new medicines can help reduce flare-ups, improve breathing, and make everyday life better.
Chronic Obstructive Pulmonary Disease (COPD)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Urinary Tract Infection, Acute Uncomplicated Pyelonephritis, Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, and Complicated Intra-Abdominal Infection due to Carbapenem Resistant Enterobacterales (OP0595-6)
This study looks at new medicines for serious bacterial infections like complicated urine infections, pneumonia, and tummy infections. Researchers want to see if these new treatments work better and are safer than current standard care, especially for infections resistant to common antibiotics.
Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
This study looks at a new drug, OPT-302, combined with an existing treatment (Lucentis) for 'wet' age-related macular degeneration (AMD). It aims to see if the combination works better than Lucentis alone to improve or maintain vision over one year.
Neovascular age-related macular degeneration (wet AMD)Latvia - RecruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking at a new medicine called Vyvgart for people with Thyroid Eye Disease. It aims to see if the medicine can help reduce bulging eyes and improve eye health, compared to a dummy medicine, over 24 weeks.
Thyroid Eye Disease (TED)Latvia - RecruitingTherapeutic confirmatory (Phase III)
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
This study is looking at the long-term safety of a medicine called Avacincaptad pegol for people with a serious eye condition called geographic atrophy. It's for those who have already been in a previous study using this medicine.
geographic atrophyLatvia - RecruitingTherapeutic exploratory (Phase II)
CDX0159-07: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Chronic Inducible Urticaria
This study is testing a new medicine called Barzolvolimab for people with chronic inducible urticaria (hives that can be triggered). It aims to see if the medicine can stop hives from appearing when triggered by cold or scratching, and if it's safe to use.
Chronic Inducible UrticariaLatvia - RecruitingTherapeutic exploratory (Phase II)
A MULTICENTER, OPEN-LABEL, EVALUATOR-BLINDED, RANDOMIZED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SINGLE-DOSE INTRAVENOUS ORITAVANCIN FOR THE TREATMENT OF PEDIATRIC SUBJECTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS
This study is looking at how safe a new medicine called Oritavancin (also known as ORBACTIV or KIMYRSA) is for children with serious skin infections. Researchers want to see if it causes any problems when given as a single dose through a drip.
Acute Bacterial Skin and Skin Structure InfectionsLatvia - RecruitingTherapeutic confirmatory (Phase III)
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2)
This study is testing a new medicine, ESK-001, for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe and helps clear up skin patches better than a dummy pill or an existing medicine (Otezla).
Moderate to Severe Plaque PsoriasisLatvia